Add to Watchlist
View Current for TRIL
View SuperFeed for TRIL
View Charts for TRIL
Add or remove $TRIL from your watchlists:
Hang tight! We're updating your watchlist data.
This might take a minute...
Trillium Therapeutics Inc
Health Care
As of November 17, 2021, Trillium Therapeutics Inc. was acquired by Pfizer Inc. Trillium Therapeutics Inc., a clinical stage immuno-oncology company,… more
Thread Explorer
Explore popular threads around $TRIL
There are no threads for this stock
Go to Thread Explorer
Chart Explorer
Explore recent charts, graphs, and media
There are no charts for this stock
Latest News
Get the latest breaking news from the community
There is no recent news for this stock
Loading news, hang tight...
Google Search Trends - Past 12 months
Instantly visualize search trends for this specific symbol
Company Profile
As of November 17, 2021, Trillium Therapeutics Inc. was acquired by Pfizer Inc. Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Cambridge, Massachusetts.Market Cap Type: Small